Oxford Biomedica plc (LON:OXB - Get Free Report) insider Roch Doliveux purchased 67,000 shares of the firm's stock in a transaction on Friday, August 15th. The shares were purchased at an average cost of GBX 450 per share, with a total value of £301,500.
Oxford Biomedica Price Performance
Shares of OXB traded up GBX 6.08 during trading hours on Friday, hitting GBX 539.08. 212,122 shares of the company were exchanged, compared to its average volume of 226,097. The company has a market capitalization of £573.05 million, a PE ratio of -4.01 and a beta of 1.09. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67. The firm has a fifty day simple moving average of GBX 386.88 and a 200-day simple moving average of GBX 339.31. Oxford Biomedica plc has a one year low of GBX 232.50 and a one year high of GBX 540.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on OXB shares. Peel Hunt reissued a "buy" rating and set a GBX 451 price objective on shares of Oxford Biomedica in a research note on Friday, August 1st. JPMorgan Chase & Co. reduced their price objective on Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating for the company in a research note on Tuesday, July 15th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Oxford Biomedica currently has an average rating of "Hold" and a consensus target price of GBX 410.33.
Get Our Latest Analysis on Oxford Biomedica
About Oxford Biomedica
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Featured Articles
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.